Peer-reviewed veterinary case report
Toceranib treatment outcomes for dogs with aortic body tumors
By Coto, Giovanna M et al.·Published in Frontiers in veterinary science·2021·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas.
- Species:
- dog
Plain-English summary
A group of dogs with aortic body tumors, known as chemodectomas, were treated with a medication called toceranib phosphate to see how well it worked. Out of 27 dogs, 89% showed improvement, with many experiencing either complete or partial remission, or stable disease for over 10 weeks. The average survival time for dogs treated with toceranib alone was about 478 days, which was similar to those who received additional treatments. This suggests that toceranib could be an effective option for managing these tumors, but more studies are needed to confirm its benefits.
People also search for: dog heart tumor treatment · chemodectoma in dogs · toceranib phosphate for dogs · canine cardiac tumor survival rate
Abstract
Aortic body tumors, specifically chemodectomas, are the second most common type of canine cardiac tumor; however, information about treatment is currently lacking. This study included dogs with a presumptive or definitive diagnosis of an aortic body chemodectoma that underwent treatment with toceranib phosphate. Cases were solicited via the American College of Veterinary Internal Medicine Cardiology, Internal Medicine, and Oncology listservs using an electronic survey. Cox multivariate analysis of factors potentially impacting survival time was completed. Twenty-seven (27) cases were included in analysis. The clinical benefit rate (complete remission, partial remission, or stable disease >10 weeks) was 89%. A median survival time of 478 days was found for those receiving toceranib alone (= 14), which was not statistically different from those treated with additional modalities (521 days). No factors evaluated statistically impacted outcome. Further, prospective studies are warranted to evaluate the use of toceranib for the treatment of canine aortic body chemodectomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33614771/